Filing Flows › ADC Therapeutics SA (ADCT) › Royalties revenue
ADC Therapeutics SA (ADCT) Royalties revenue by quarter
ADC Therapeutics SA's Royalties revenue was $614K in Q2 2026 (second quarter 2026), -25% from Q1 2026. Over the last 6 quarters it ranged from $614K (Q2 2026) to $818K (Q1 2026).
| Quarter | Royalties revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $614K | -25% | -19% |
| Q1 2026 | $818K | +10% | +30% |
| Q4 2025 | $746K | +10% | — |
| Q3 2025 | $677K | -10% | — |
| Q2 2025 | $754K | +20% | — |
| Q1 2025 | $629K | — | — |
Q2 2026 at a glance
ADC Therapeutics SA, Q2 2026: revenue $19.2M (+2% year over year), operating margin -132.0%, net loss $16.6M, operating cash flow −$11.8M. The chart follows the revenue to costs, profit and cash.
Questions
What is ADC Therapeutics SA's Royalties revenue?
ADC Therapeutics SA's Royalties revenue was $614K in Q2 2026 (second quarter 2026), -25% from Q1 2026.
How has ADC Therapeutics SA's Royalties revenue changed?
Over the last 6 quarters it ranged from $614K (Q2 2026) to $818K (Q1 2026).